Loading...

Pipeline Advances And Acquisitions Will Expand Therapeutic Horizons

Published
07 Nov 24
Updated
01 May 25
AnalystConsensusTarget's Fair Value
€109.22
27.2% undervalued intrinsic discount
04 Sep
€79.50
Loading
1Y
-24.0%
7D
-5.9%

Author's Valuation

€109.2

27.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 13%

Shared on23 Apr 25
Fair value Increased 4.57%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 7.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.86%

Shared on26 Mar 25
Fair value Decreased 2.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 1.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 2.53%

AnalystConsensusTarget has increased revenue growth from 2.6% to 6.2%.